Neoadjuvant anastrozole alone or with gefitinib in early breast cancer. Homo sapiens
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Trial 223 was a placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. We used patients from arm B and C: anastrozole 1mg/d for the duration of the 16 week period plus placebo 1 tablet/d orally for 2 weeks. Patients in arm B were followed by gefitinib 250mg/d orally for 14 weeks whereas patients in arm C continued with placebo for 14 weeks. Overall design: 96 samples
创建时间：
2013-07-16
